RxDoctor Payments Data

Marc London, MD

Neurology · West Nyack, NYNPI 1720140767

Payments from drug & device makers

$30,961in general payments, 2019–2025

Across 1,024 payments — averaging $30.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$18K
  • UCB, Inc.$935
  • Lilly USA, LLC$911
  • Kyowa Kirin, Inc.$734
  • Pfizer$617
  • Eisai Inc.$604
  • plus $10K from 54 others

What the payments were for

  • Speaking & faculty fees$10,93335%
  • Travel & lodging$9873%
  • Food & beverage$19,02161%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)303$17,501
UCB, Inc.55$935
Lilly USA, LLC53$911
Kyowa Kirin, Inc.37$734
Pfizer40$617
Eisai Inc.27$604
Novartis34$523
SK Life Science, Inc.22$480
Amgen23$476
EMD Serono, Inc.20$442
Amneal Pharmaceuticals LLC25$390
Sanofi16$337
Sumitomo Pharma America, Inc.16$336
Lundbeck LLC14$332
Acadia Pharmaceuticals Inc17$328
Supernus Pharmaceuticals, Inc.22$307
Bristol Myers Squibb25$302
Biogen16$287
Adamas Pharmaceuticals, Inc.18$285
Upsher-smith Laboratories LLC17$284
Grifols USA, LLC14$283
AstraZeneca(2 entities)13$278
Genentech USA, Inc.12$276
Biohaven Pharmaceuticals, Inc.19$274
Otsuka America Pharmaceutical, Inc.8$199
Teva Pharmaceuticals USA, Inc.11$190
Abbott6$173
Johnson & Johnson(2 entities)7$162
Currax Pharmaceuticals LLC12$161
Biohaven Pharmaceutical Holding Company Ltd.8$160
Argenx US, Inc.5$155
Aucta Pharmaceuticals, Inc.10$154
Sunovion Pharmaceuticals Inc.8$139
CSL Behring5$133
Almatica Pharma LLC4$118
Assertio Therapeutics, Inc.6$116
Avanir Pharmaceuticals, Inc.4$106
Neurelis, Inc.3$106
Arbor Pharmaceuticals, Inc.7$95
Tanabe Pharma America, Inc.5$88
Vertical Pharmaceuticals, LLC5$88
Catalyst Pharmaceuticals, Inc.4$87
Scilex Pharmaceuticals Inc.4$83
Neurocrine Biosciences, Inc.4$73
Azurity Pharmaceuticals, Inc.3$68
Mallinckrodt Hospital Products Inc.3$66
Xeris Pharmaceuticals, Inc.3$64
Axsome Therapeutics, Inc.2$62
Medtronic3$59
Boston Scientific2$55
Alnylam Pharmaceuticals Inc.2$52
Portola Pharmaceuticals, LLC2$49
Impel Pharmaceuticals Inc.2$48
Acorda Therapeutics, Inc3$48
TG Therapeutics, Inc.2$47
Aprecia Pharmaceuticals, LLC3$43
ANI Pharmaceuticals, Inc.1$31
Promius Pharma LLC2$30
Corium, LLC1$27
Takeda Pharmaceuticals U.S.A., Inc.1$27

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,961 in reported general payments places this provider in the 80th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$200,062
Medicare patients
705
Services billed
1,661

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate31$39,270
RytaryCarbidopa/Levodopa19$21,732
Keppra XrLevetiracetam30$18,207
Pregabalin137$6,083
Rivastigmine13$4,118
Memantine Hcl169$3,625
Levetiracetam109$3,594
Quetiapine Fumarate36$3,333
Memantine Hcl ErMemantine Hcl23$3,129
Donepezil Hcl293$2,882
Gabapentin169$2,767
Carbidopa-LevodopaCarbidopa/Levodopa68$2,363
Oxcarbazepine36$1,423
Levetiracetam ErLevetiracetam29$1,122
Rasagiline Mesylate13$1,118

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$617$39,27031 claims
Amneal Pharmaceuticals LLCRytary$390$21,73219 claims
Upsher-smith Laboratories LLCTopiramate$284$1,05041 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,623 neurology providers in New York.

Other neurology in West Nyack

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →